VIDEO - Highlights from DC Finance Discussion Series - "Physician Perspectives: Improving Breast Cancer Outcomes with Perimeter’s Disruptive Medical Technology and AI”
DC Finance has built an international network of high-net worth individuals, family offices, and investors that today reaches over 2,000 families around the world representing over $500 billion in assets. Denny Chared, founder of DC Finance, recently hosted a webinar with Perimeter Medical Imaging AI (PINK.V) to get the physician's perspective on improving breast cancer outcomes with Perimeter's disruptive medical technology. Dr. Ted James, Chief of Breast Cancer Surgery at Harvard Medical School and Dr. Frank Prendergast, former Director Emeritus of the Mayo Clinic’s Comprehensive Cancer Centre joined Jeremy Sobotta, CEO of Perimeter to articulate how the company is working to transform breast cancer surgery with advanced, real-time, ultra-high resolution medical imaging technology and AI tools.
This presentation contains forward-looking forward statements. Forward-looking statements include statements regarding the Company’s future financial position, business strategy, projected costs, strategic partnering, the capabilities of the Company’s platform, and plans and objectives of management for future operations. You are cautioned not to place undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The forward looking statements in this presentation include but are not limited to: future plans for clinical trials, progress of and reports of results from clinical studies, clinical development plans, product development plans, other products not yet developed or acquired, product success, plans for FDA filings and their subsequent approvals, other regulatory filings by Perimeter or Perimeter’s partners, our ability to commercialize the product(s), and the safety and efficacy of our product. Note that the OTIS 2.0 Optical Coherence Tomography System is an FDA Cleared device, not currently marketed in the US. The OTIS 2.0 Optical Coherence Tomography System is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. The safety and effectiveness of this device for diagnostic analysis (i.e. differentiating normal versus specific abnormalities) in any tissue microstructure or specified disease has not been evaluated. OTIS is not currently cleared for sale in Canada, the EU or other jurisdictions. Actual results could differ materially from our current expectations as a result of many risks and uncertainties. Risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described the joint information circular dated May 12, 2020, prepared in respect of the securityholder meetings held on June 17, 2020, a copy of which is available on Perimeter's SEDAR profile at www.sedar.com. All forward-looking statements are based on information available to the Company on this date and, except as required under applicable law, the Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.